IMMX
HealthcareImmix Biopharma, Inc.
$5.10
$-0.33 (-6.08%)
Jan 5, 2026
Price History (1Y)
Analysis
Immix Biopharma, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $268.75 million and 18 employees, it is a relatively small player within its industry. The company's financial health is marked by significant losses. Immix Biopharma has reported net income of -$23,562,836 over the trailing twelve months, accompanied by EBITDA of -$23,836,024 and free cash flow of -$6,578,808. Additionally, it has a gross margin, operating margin, and profit margin of 0.0%. The company's balance sheet shows cash reserves of $15.95 million and debt of $1.11 million, resulting in a debt-to-equity ratio of 13.39. Valuation metrics for Immix Biopharma include a forward P/E ratio of -7.91 and an EV/EBITDA ratio of -7.03. The company's price to book ratio stands at 20.40.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Visit website →Key Statistics
- Market Cap
- $268.75M
- P/E Ratio
- N/A
- 52-Week High
- $7.73
- 52-Week Low
- $1.34
- Avg Volume
- 990.38K
- Beta
- 0.31
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 18